Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

Gladys Morrison(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Teresa Klinowska(AstraZeneca (United Kingdom)), Mario Giuliano(Regione Campania), Xiaoyong Fu(King University), Sarmistha Nanda(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Martin J. Shea(Baylor College of Medicine), Tao Wang(Pfizer (United States)), C. Kent Osborne(Baylor College of Medicine)
Breast Cancer Research and Treatment
February 19, 2014
10.1007/s10549-014-2878-x
Cited by 61

Related Papers

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485